“I can see if I can see a potential to be able to get this approved by year end.”

In context

“. But, we are also equally investing in mapping and ensuring that our mapping superiority, is maintained. As obviously competitors are launching their own mapping systems. So we will continue to invest in that also and our ability to stay ahead is, I think, very strong. So I think from a forecast perspective, I expect global EP growth to accelerate. it is in the teens right now. It will accelerate in the second half. For sure and outperforming the market. And I expect that momentum that we are building this year to carry through to next year. And I think we will get an additional boost, into this EP portfolio. With our new LAA device I think feedback there has been extremely positive. And we filed with the FDA. I think here, I will probably feel a little bit more comfortable saying, yeah. I can see if I can see a potential to be able to get this approved by year end. And then with that, we will have strong momentum going into next year with both rollout of Tactiflex Duo in The US continued acceleration of Bolt in the US, launching our next generation LAA device also. So I see that momentum continue into next year. Matt Taylor: Great. Thanks so much. Yep. Operator: Thank you. Our next question comes from Travis Steed from BofA Securities. Your line is open. Travis Steed: Hey, Robert. Thanks for taking the question. I guess as we move into the second half of this year, investors are going to start looking more into next year. Just curious how you think about the Abbott portfolio in the next year if this is like kind of a year that sets up for better growth. You have got easier nutrition comps, expanding coverage in Libre. You talked about EP acceleratin”